Jasper Therapeutics seeks approval to increase authorized common stock from 490,000,000 shares to 675,000,000. The change matters because the Merger Agreement requires authorization sufficient to permit conversion of Preferred Stock issued in the Kira transaction, while the board retains discretion over implementation.
Key Highlights
- Jasper Therapeutics will hold a virtual special meeting on September 30, 2026.
- Kira shareholders received 5,195,009 common shares and 4,644,977 shares of convertible preferred stock.
- Jasper agreed to sell approximately 4.7 million Preferred Shares for approximately $132 million in cash.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is asking stockholders to raise its authorized common-stock count from 490,000,000 shares to 675,000,000. The proposed amendment would leave the authorized numbers of non-voting common stock and preferred stock unchanged, while the board would retain discretion over whether to implement the increase.
Share Authorization Tied to Kira Transaction
Jasper will put the proposal to stockholders at a virtual special meeting on September 30, 2026. The meeting will also cover a proposed Reverse Stock Split of voting common stock and a possible adjournment if additional proxy votes are needed. The authorized-share amendment follows Jasper’s Acquisition of Kira Pharmaceuticals on July 16, 2026. Under the Merger Agreement, Kira shareholders received 5,195,009 shares of common stock and 4,644,977 shares of non-voting convertible preferred stock with a $0.0001 Par Value per share. Jasper also agreed to sell approximately 4.7 million preferred shares for approximately $132 million in cash. Its current Capital authorization totals 502,000,000 shares, comprising 490,000,000 common shares, 2,000,000 non-voting common shares and 10,000,000 preferred shares.
Board Retains Discretion Over Implementation
The Merger Agreement requires Jasper to seek enough authorized common stock to permit conversion of all preferred stock, including shares issued under the purchase agreement. Stockholder approval would allow the board to determine whether to enact the authorized-share increase. The board also may decline to implement the increase if it decides that doing so is not in Jasper’s or its stockholders’ best interests. Jasper currently does not intend to implement the increase if the reverse stock split takes effect. As of the record date, 33,274,561 common shares were issued and outstanding. The reverse stock split proposal would not reduce the authorized number of common shares.




Please wait processing your request...